COVID-19

[Adrenomed AG] Adrenomed AG announced that its proprietary sepsis drug candidate Adrecizumab received a funding commitment of € 7.4 million from the German Federal Ministry of Education and Research as part of the German funding initiatives for the clinical development of COVID-19 drugs and their manufacturing capabilities.

[Immunity] Scientists assessed affinity and neutralization potency against the Omicron variant of several hundred naturally expressed memory B cell-derived monoclonal IgG antibodies from vaccinated COVID-19-recovered and -naïve individuals.

[Experimental and Molecular Medicine] Investigators discuss a proposed interaction between SARS-CoV-2 and Toll-like receptor 2 (TLR2) in the central nervous system.

[Journal of Tissue Engineering and Regenerative Medicine] The authors present the current landscape of the field and highlights some interesting findings on MSC-derived extracellular vesicles in the context of COVID-19, including in silico, in vitro, in vivo and case reports.

[Nature Methods] Scientists overview the current effort to apply both human pluripotent stem cell-derived organoids and adult organoids to study SARS-CoV-2 tropism, host response and immune cell-mediated host damage, and perform drug discovery and vaccine development.

[Science Translational Medicine] Given our emerging appreciation for the importance of additional antibody functions beyond neutralization, we profiled the post-boost binding and functional capacity of humoral immune responses induced by the BNT162b2 and mRNA-1273 vaccines in a cohort of hospital staff.